These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 16791450

  • 1. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
    Holloway SE, Beck AW, Shivakumar L, Shih J, Fleming JB, Brekken RA.
    Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
    [Abstract] [Full Text] [Related]

  • 2. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.
    Bockhorn M, Tsuzuki Y, Xu L, Frilling A, Broelsch CE, Fukumura D.
    Clin Cancer Res; 2003 Sep 15; 9(11):4221-6. PubMed ID: 14519649
    [Abstract] [Full Text] [Related]

  • 3. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE.
    Cancer Res; 2000 Sep 15; 60(18):5117-24. PubMed ID: 11016638
    [Abstract] [Full Text] [Related]

  • 4. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
    Camp ER, Yang A, Liu W, Fan F, Somcio R, Hicklin DJ, Ellis LM.
    Clin Cancer Res; 2006 Apr 15; 12(8):2628-33. PubMed ID: 16638876
    [Abstract] [Full Text] [Related]

  • 5. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM.
    Cancer; 2000 Aug 01; 89(3):488-99. PubMed ID: 10931447
    [Abstract] [Full Text] [Related]

  • 6. Vascular endothelial growth factor as a marker of tumor endothelium.
    Brekken RA, Huang X, King SW, Thorpe PE.
    Cancer Res; 1998 May 01; 58(9):1952-9. PubMed ID: 9581838
    [Abstract] [Full Text] [Related]

  • 7. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
    Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ.
    Cancer Res; 1999 Oct 15; 59(20):5209-18. PubMed ID: 10537299
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice.
    Tseng JF, Farnebo FA, Kisker O, Becker CM, Kuo CJ, Folkman J, Mulligan RC.
    Surgery; 2002 Nov 15; 132(5):857-65. PubMed ID: 12464871
    [Abstract] [Full Text] [Related]

  • 10. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma.
    Shiose S, Sakamoto T, Yoshikawa H, Hata Y, Kawano Y, Ishibashi T, Inomata H, Takayama K, Ueno H.
    Invest Ophthalmol Vis Sci; 2000 Aug 15; 41(9):2395-403. PubMed ID: 10937546
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1558-70. PubMed ID: 17077358
    [Abstract] [Full Text] [Related]

  • 12. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
    Li J, Huang S, Armstrong EA, Fowler JF, Harari PM.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1477-85. PubMed ID: 16029810
    [Abstract] [Full Text] [Related]

  • 13. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
    Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM, Pollock RE.
    Cancer Res; 2000 Jul 01; 60(13):3655-61. PubMed ID: 10910082
    [Abstract] [Full Text] [Related]

  • 14. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, McConkey DJ.
    Cancer Res; 2004 Jul 01; 64(13):4601-10. PubMed ID: 15231672
    [Abstract] [Full Text] [Related]

  • 15. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
    Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y.
    Cancer Res; 2000 Oct 01; 60(19):5565-70. PubMed ID: 11034104
    [Abstract] [Full Text] [Related]

  • 16. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR.
    Cancer Res; 1999 Jul 15; 59(14):3374-8. PubMed ID: 10416597
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.
    Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li Q, Le X, Wang H, Yao J, Xie K.
    Cancer; 2007 Dec 15; 110(12):2682-90. PubMed ID: 17973266
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
    Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):678-89. PubMed ID: 15701856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.